Lung CancerERAS-NUTRINCT07785791
ERAS Compliance and Nutritional Outcomes After Lung Cancer Surgery
An observational study of Lung Cancer, run by Bursa City Hospital at 1 site in Turkey (Türkiye).
Trial summary
This prospective observational study will evaluate the association between ERAS protocol compliance and postoperative nutritional outcomes in 120 patients undergoing lung cancer surgery. ERAS compliance will be recorded, and patients will be classified as having high, moderate, or low compliance. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Routine ERAS Perioperative Care
- How many people
- 120 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 May 2026to 15 Sep 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients undergoing elective lung cancer surgery at Bursa City Hospital.
Who may be able to join
- Age between 18 and 85 years
- Scheduled for elective lung cancer surgery under general anesthesia
- ASA physical status I-III
- Able to provide written informed consent
Who cannot join
- Emergency surgery
- Preoperative total parenteral nutrition
- Advanced organ failure
- Uncontrolled metabolic disease
- Pregnancy or breastfeeding
- Inability to provide informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Evaluation of the Effect of Compliance With the Enhanced Recovery After Surgery Protocol on Postoperative Nutritional Risk and Prognostic Nutritional Index in Patients Undergoing Lung Cancer Surgery
This prospective observational study will evaluate the association between ERAS protocol compliance and postoperative nutritional outcomes in 120 patients undergoing lung cancer surgery. ERAS compliance will be recorded, and patients will be classified as having high, moderate, or low compliance. NRS-2002 and PNI will be assessed before surgery and at postoperative 48 hours. Hospital stay and postoperative complications will also be evaluated.
Read the detailed description
This single-center observational cohort study will include 120 patients aged 18-85 years undergoing elective lung cancer surgery. No intervention will be assigned. ERAS compliance will be categorized as high (≥80%), moderate (60-79%), or low (<60%). Changes in NRS-2002 and PNI, hospital stay, and postoperative complications will be evaluated using routine clinical data.
- Conditions
- Lung Cancer
- Being tested
- Routine ERAS Perioperative Care
- Keywords
- Enhanced Recovery After Surgery, ERAS Compliance, Nutritional Risk, Prognostic Nutritional Index, NRS-2002, Thoracic Surgery
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine ERAS Perioperative CareOther
Patients receive routine perioperative care according to the institutional ERAS protocol. No intervention is assigned by the investigators. ERAS compliance is assessed observationally.
| Study group | Role | What they receive |
|---|---|---|
| High ERAS Compliance | Patients with an overall ERAS protocol compliance rate of 80% or greater. Receives: Other: Routine ERAS Perioperative Care | |
| Moderate ERAS Compliance | Patients with an overall ERAS protocol compliance rate between 60% and 79%. Receives: Other: Routine ERAS Perioperative Care | |
| Low ERAS Compliance | Patients with an overall ERAS protocol compliance rate below 60%. Receives: Other: Routine ERAS Perioperative Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Nutritional Risk Screening 2002 Score
NRS-2002 will be assessed before surgery and at postoperative 48 hours. The score ranges from 0 to 7, with higher scores indicating greater nutritional risk. Change will be calculated as the postoperative score minus the preoperative score.
Measured: From preoperative assessment to 48 hours after surgery
Secondary outcomes (4)
Change in Prognostic Nutritional Index
PNI will be calculated as (10 × serum albumin [g/dL]) + (0.005 × total lymphocyte count [/mm³]). Higher values indicate better nutritional status. Change will be calculated as the postoperative value minus the preoperative value.
Measured: From preoperative assessment to 48 hours after surgery
Length of Hospital Stay
Number of days from the date of surgery to hospital discharge.
Measured: From surgery to hospital discharge, assessed up to 30 days
Postoperative Complications
Occurrence of any postoperative complication documented during hospitalization or at the 30-day follow-up.
Measured: From surgery to 30 days after surgery
ERAS Protocol Compliance
The number of applied ERAS components divided by the total number of applicable components and expressed as a percentage. Higher percentages indicate greater compliance.
Measured: Perioperative/Periprocedural
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start15 May 2026
- Primary completion15 Sep 2026
- Study completion15 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bursa City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Emre Ulusoy, Bursa City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07785791
- Sponsor's protocol ID
- EU02
- Acronym
- ERAS-NUTRI
- Status last verified
- Sep 2026
- First submitted
- 20 Aug 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because participant consent and ethics approval do not include public or external sharing of individual-level data.
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of the Effect of Compliance With the Enhanced Recovery After Surgery Protocol on Postoperative Nutritional Risk and Prognostic Nutritional Index in Patients Undergoing Lung Cancer Surgery
- ClinicalTrials.gov ID
- NCT07785791
- Acronym / sponsor ID
- ERAS-NUTRI / EU02
- Conditions
- Lung Cancer
- Keywords
- Enhanced Recovery After Surgery, ERAS Compliance, Nutritional Risk, Prognostic Nutritional Index, NRS-2002, Thoracic Surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Bursa City HospitalOther government
- Study start
- 15 May 2026 (actual)
- Primary completion
- 15 Sep 2026 (actual)
- Study completion
- 15 Sep 2026 (actual)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective observational study will evaluate the association between ERAS protocol compliance and postoperative nutritional outcomes in 120 patients undergoing lung cancer surgery. ERAS compliance will be recorded, and patients will be classified as having high, moderate, or low compliance. NRS-2002 and PNI will be assessed before surgery and at postoperative 48 hours. Hospital stay and postoperative complications will also be evaluated.
Detailed description
This single-center observational cohort study will include 120 patients aged 18-85 years undergoing elective lung cancer surgery. No intervention will be assigned. ERAS compliance will be categorized as high (≥80%), moderate (60-79%), or low (<60%). Changes in NRS-2002 and PNI, hospital stay, and postoperative complications will be evaluated using routine clinical data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High ERAS Compliance | – | Other: Routine ERAS Perioperative CarePatients with an overall ERAS protocol compliance rate of 80% or greater. |
| Moderate ERAS Compliance | – | Other: Routine ERAS Perioperative CarePatients with an overall ERAS protocol compliance rate between 60% and 79%. |
| Low ERAS Compliance | – | Other: Routine ERAS Perioperative CarePatients with an overall ERAS protocol compliance rate below 60%. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients undergoing elective lung cancer surgery at Bursa City Hospital.
Key inclusion criteria (4 listed)
- Age between 18 and 85 years
- Scheduled for elective lung cancer surgery under general anesthesia
- ASA physical status I-III
- Able to provide written informed consent
Key exclusion criteria (6 listed)
- Emergency surgery
- Preoperative total parenteral nutrition
- Advanced organ failure
- Uncontrolled metabolic disease
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Routine ERAS Perioperative CarePatients receive routine perioperative care according to the institutional ERAS protocol. No intervention is assigned by the investigators. ERAS compliance is assessed observationally. | Other | High ERAS Compliance, Low ERAS Compliance, Moderate ERAS Compliance |
Primary outcome
Change in Nutritional Risk Screening 2002 Score
Time frame: From preoperative assessment to 48 hours after surgery
NRS-2002 will be assessed before surgery and at postoperative 48 hours. The score ranges from 0 to 7, with higher scores indicating greater nutritional risk. Change will be calculated as the postoperative score minus the preoperative score.
4 secondary outcomes
Change in Prognostic Nutritional Index
Time frame: From preoperative assessment to 48 hours after surgery
Length of Hospital Stay
Time frame: From surgery to hospital discharge, assessed up to 30 days
Postoperative Complications
Time frame: From surgery to 30 days after surgery
ERAS Protocol Compliance
Time frame: Perioperative/Periprocedural
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because participant consent and ethics approval do not include public or external sharing of individual-level data.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by Bursa City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Nutritional Risk Screening 2002 Score (time frame: From preoperative assessment to 48 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.